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Summary
PRINCIPAL: Electroconvulsive therapy (ECT) is a treat-
ment option for patients with bipolar disorder (BD). Alter-
ations of markers have been reported following ECT. Aim:
the aim of the present study was to assess the effect of ad-
junctive celecoxib on the serum cytokines of patient with
BD who were undergoing ECT.
METHODS: This study was a randomised, double-blind,
placebo-controlled trial in 48 patients who were diagnosed
with BD and ordered to undergo six or more ECT sessions.
Patients were randomly assigned to receive either placebo
or celecoxib (200 mg twice daily) starting a day before the
first ECT and continuing throughout the end of the sixth
ECT. Blood levels of interleukin-1β (IL-1β), interleukin-6
(IL-6), tumour necrosis factor-α (TNF-α) and high-sensit-
ivity C-reactive protein (hsCRP) were measured before the
first ECT and repeated after the first, the third and the sixth
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ECT sessions. Data were analysed by using SPSS version
13.
RESULTS: Twenty-five patients (mean ± standard devi-
ation age of 33.64 ± 9.97 years) were assigned to the cele-
coxib group and 23 patients (mean age of 32.61 ± 9.82
years) to the placebo group. This study found that the level
of TNF-α was significantly lower (p = 0.04, t = 2.14, de-
grees of freedom 46) in patients receiving celecoxib com-
pared with those on placebo at the last session of ECT.
However, the other factors studied did not show any signi-
ficant changes throughout the trial.
CONCLUSIONS: Celecoxib was concluded to reduce
TNF-α levels significantly in the patients at the end of the
study. However, the differences in IL-1β, IL-6 and hsCRP
between the two groups were not significant.
Trial registration number: IRCT201201247202N2
Key words: celecoxib; COX-II inhibitor; bipolar disorder;
inflammatory cytokines; clinical trial
Introduction
Bipolar disorder (BD) is considered to be a chronic, seri-
ous, and debilitating mental disorder [1, 2]. Although there
is a discrepancy in the estimated reports of life-time preval-
ence of bipolar disorder, the number has been proposed to
be between 1.3% to more than 5%, depending on whether
or not BD-I, BD-II or the combination of these two disor-
ders were considered [3]. The immune system has been re-
cently receiving a lot of attention in the pathophysiology of
psychiatric disorders [4, 5].
Activation of inﬂammatory cytokines [4, 6] as well as in-
creased plasma levels of interleukin (IL) 1β, IL-6, C-re-
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active protein (CRP) and tumour necrosis factor-α (TNF-
α), have been reported in BD patients [7]. In particular,
increased levels of plasma soluble interleukin-2 receptor
(sIL-2R) [5], IL-2, IL-4 [8], IL-6 [8, 9], CRP [10], IL-8 [11]
and TNF-α [9, 11] have been proposed in manic patients.
Besides, significantly higher levels of IL-8 and TNF-α
have been shown in bipolar depressed patients when com-
pared to the healthy subjects [11].
Patients suffering from BD seem to have much less long-
term symptomatic and cognitive recovery than previously
thought [12]. Although there are several treatment options
for BD, a considerable number of patients do not respond
satisfactorily to any treatment [13]. Even though medica-
tions are generally considered the first-line treatment op-
tion for acute bipolar depression [14] and mania [15], elec-
troconvulsive therapy (ECT) is also utilised frequently for
the management of these disorders [13].
The role of ECT in the treatment of different phases of
depression, mania and mixed episodes has been evaluated
in various studies. In a study by Medda et al. [16], ECT
produced a considerable improvement in patients with res-
istant unipolar, bipolar I and bipolar II depression. In a
systematic review regarding the treatment of patients with
mixed state, Valentì et al. found three qualified studies that
indicated the safety and efficacy of ECT [17]. In a recent
review, it was mentioned that even though there are not
many randomised, controlled trials on the effects of ECT
in BD, this procedure has shown a good clinical efficacy,
especially in medication resistant patients diagnosed with
this disorder [18].
ECT has been reported to affect monoamines,
neuropeptides, neurotrophic factors, hormones and several
neurotransmitters with their receptors [19, 20]. Addition-
ally, this procedure may also affect immune system, cy-
tokines, increase plasma cortisol or adrenocorticotrophic
hormone (ACTH), and alter natural killer cell activity after
ECT procedure [21]. It should be noted that some agents
such as nonsteroidal anti-inflammatory drugs (NSAIDs)
have been reported to reduce inflammation and inflammat-
ory mediators [22]. Traditional NSAIDs like ibuprofen and
selective cyclo-oxygenase (COX) II inhibitors are known
to have analgesic, antipyretic and anti-inﬂammatory prop-
erties owing to their effects on the active site of COX-II en-
zyme [23]. Celecoxib is among the COX-II inhibitors and
is reported to inhibit prostaglandin E2 production [24] and
decrease proinflammatory cytokines [25]. And inhibition
of the activation of TNF-α-induced NF-kB (nuclear factor
kappa-light-chain-enhancer of activated B cells) [27] have
been also reported with this drug.
Recently, celecoxib has been evaluated as an adjuvant in
different psychiatric disorder like schizophrenia [25, 28,
29], depressive or mixed episodes of bipolar disorder [30],
obsessive-compulsive disorder [31] and depression [32,
33].
There are several different cytokines that play a role in the
regulation of immune function. Besides, the role of some
cytokines such as IL-1β, IL-6, TNF-α in the central nervous
system [7] has been reported in the literature. To the best
of our knowledge the effect of ECT on cytokines in BD pa-
tients and the role of celecoxib in this regard have not been
evaluated so far. Therefore, the current study was aimed to
assess the effects of adjunctive celecoxib or placebo, in BD
patients undergoing ECT, on serum cytokines and high-
sensitivity CRP (hsCRP).
Material and methods
Patients and intervention
This parallel, randomised, double-blind clinical trial with
(identifier number of IRCT201201247202N2) was re-
gistered at irct.ir and was conducted at Roozbeh Hospital,
affiliated with Tehran University of Medical Sciences
(TUMS). The study was approved by the ethics committee
of the TUMS and patients or their guardians gave signed
informed consent prior to entering this study. Inpatients
from 17 to 70 years of age, who met the DSM IV-TR dia-
gnostic criteria for BD and who were ordered to receive
six or more ECT treatments by their psychiatrists, were
included in this study. The principal investigator was the
person who randomised the patients, based on a table of
random numbers. Both patients and other researchers were
blinded to whether the participant was taking celecoxib or
placebo until after the completion of the study. The shapes
of the placebo or celecoxib capsules were the same and
they were packed in the envelopes numbered accordingly.
The pharmacy in the hospital provided the medications for
the patients after receiving the order based on the number
assigned to each patient.
Celecoxib was administered at the dose of 200 mg twice
daily starting a day before the first ECT and continuing
with the same dose throughout the end of the 6th ECT ses-
sion.
Patients with a history of hypersensitivity to NSAIDs,
rheumatologic disease, active peptic ulcer disease, inflam-
matory bowel disease, advanced chronic liver or kidney
disease, chronic obstructive pulmonary disease, and uncon-
trolled heart failure (New York Heart Association [NYHA]
class ≥III) as well as those taking NSAIDs or corticost-
eroids concomitantly and pregnant women were excluded
from this study. Moreover, patients could not have received
ECT in the preceding two months.
Patients were followed up periodically by a clinical phar-
macist to detect and monitor any adverse drug reactions
(ADRs) that were reported by the patients or their care-
givers during the study.
ECT procedure
All patients received bilateral ECT, which was performed
three times per week, using ThymatroneDGx (Somatics
INC). All ECT procedures were performed between 7:30
and 9:00 a.m at Roozbeh Hospital. Patients were fasting
for at least eight hours before the ECT procedure. During
each ECT procedure, patients were administered 0.5 mg
atropine followed by 2–3 mg/kg thiopental intravenously;
succinylcholine (0.5 mg/kg) was administered as a muscle
relaxant after the induction of anaesthesia. The stimulus
intensity was determined with a dose titration procedure
(starting at 25.2 millicoulomb) and seizure threshold was
identified in the first session. Then, electrical dose was de-
termined by multiplying seizure threshold dose by 2.5 in
the following sessions. Seizure duration (tonic and clon-
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ic) was recorded by isolation of one leg by inflation of
cuff over 240 mm Hg to assess quality of seizure. If the
duration of the seizure was less than 15 seconds (aborted
seizure) then the electrical dose would be increased by
50%. Patients’ ventilation was supported using 100% oxy-
gen through a bag and mask until resumption of patients’
respiration. Electrocardiogram, arterial oxygen saturation
(pulse oximetery), noninvasive blood pressure and heart
rate of the patients were monitored continuously during the
procedure.
Blood sampling and analyses
Five ml of blood was drawn from each subject before the
first ECT and repeated 5 hours after the first, the third and
the sixth ECT sessions. Samples were centrifuged and sep-
arated and then stored at –70 °C until the time of the ana-
lyses. IL-1β, IL-6 and TNF-α concentrations were meas-
ured using a sandwich enzyme-linked immunosorbent as-
say (eBioscience, Bender MedSystemsGmbh, Vienna,
Austria) according to the instructions included. hsCRP con-
centrations were measured by turbidometry (BioSystem,
Barcelona, Spain); the limitation of detection in serum
hsCRP level was less than 0.06 mg/l.
Sample size calculation
The sample size for this study was calculated on the basis
of the previous study of Abbasi et al. [33], which compared
the lowering effect of celecoxib versus placebo on IL-6 ser-
um concentrations. The sample size was calculated to be
20 patients in each group that was determined by assuming
a standard deviation of 0.64 in the celecoxib group com-
pared with placebo (alpha = 0.05 and beta = 0.2) and about
0.4 changes in serum IL-6. Considering a possible drop-out
rate of 10%, we decided to enrol a larger number of pa-
tients, i.e., 49 patients in total.
Statistical analysis
A two-way repeated measures analysis of variance
(time–treatment interaction) was used. The two groups as
a between subjects factor (group) and the four measure-
ments during treatment as the within subjects factor (time)
were considered. Test of sphericity was based on results of
a Greenhouse–Geisser correction (details in Appendix). An
unpaired student t-test was used to compare both groups at
baseline and at the end of the trial. Wherever the distribu-
tion of data was not normal according to Kolmogorov and
Smirnov (details in Appendix), nonparametric tests such
as Mann–Whitney was used. For the comparison of demo-
graphic data the chi-square test was used. One way ana-
lysis of variance (ANOVA) was used to assess changes in
cytokines and hsCRP in different assessments during the
study period. After completion of the data gathering, the
authors initially planned to analyse the information based
on the “intention to treat” principle. However, subsequently
and after considering the principle of last observation car-
ried forward (LOCF), they decided to analyse the data
based on the “per protocol” principle (the LOCF principle
excluded a few cases because of missing data on some
repeated measurements). SPSS-13 was used for statistical
analysis of the data. The threshold for statistical signific-
ance was 0.05.
Results
Sixty-two patients out of a total of 240, who were screened
for this study from September 2010 to January 2012 at
Roozbeh Hospital, were qualified to participate in the study
and were randomly assigned to receive either celecoxib
or placebo. Forty-eight patients completed the trial (25 re-
ceived celecoxib and 23 were given placebo). The details
of number of patients recruited and dropouts are shown in
figure 1. Although all patients were in acute mood epis-
odes, they were in different disease phases. In patients re-
ceiving celecoxib, 3 patients suffered from depression, 4
were in the mixed state and the remaining were in the man-
ic phase; the number of patients with the above diagnosis
were 2 and 3 in the placebo group, respectively and the re-
Figure 1
Table 1: Demographic characteristics and baseline serum cytokine and hsCRP levels in patients receiving celecoxib (n = 25) and placebo (n = 23).
Celecoxib Placebo Signiﬁcance level (p-value)
Age (mean ± SD) 33.64 ± 9.97 32.61 ± 9.82 0.72
Female (n, %) 16 (64) 13 (56.5) 0.81‡
Mania and mixed state (n) 22 21 0.71‡
Presence of psychosis (n, %) 12 (48) 11(47.8) 0.98‡
IL-1β (pg/ml) (mean ± SD) 6.03 ± 4.99 4.62 ± 5.52 0.36
IL-6 (pg/ml) (mean ± SD) 7.72 ± 23.42 5.63 ± 10.39 0.004†
TNF-α (pg/ml) (mean ± SD) 14.88 ± 8.30 18.69 ± 7.00 0.09
hsCRP (mg/l) (mean ± SD) 7.651 ± 15.472 6.32 ± 13.08 0.81†
Mood Stabilizers (n):
Lithium
Sodium valproate
Topiramate
7
10
6
7
1
† Mann-Whitney test; ‡ chi-squared test
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maining 18 patients were manic. No significant difference
was observed in the demographic characteristic of patients
regarding age, sex, BD episode or the presence of psychos-
is between the two groups. Table 1 summarises the demo-
graphic characteristics of patients and baseline values of
serum cytokines and hsCRP.
At the beginning of the trial most patients were taking
mood stabilisers as shown in table 2. During the study, only
one patient in the placebo group and two patients in the
celecoxib group were not receiving antipsychotics. None of
the patients were administered antidepressants except one
patient in celecoxib group who received fluoxetine. Since
celecoxib may raise the serum concentration of lithium,
serum level of all patients receiving lithium were closely
monitored. Tables 2 and 3 show the mean ± standard de-
viation (SD) and median and interquartile range (IQR) of
serum cytokines and hsCRP concentrations in both groups
at each assessment respectively in our study.
It should be noted that owing to the small sample size of
the study and also the wide variation in cytokine concen-
trations, we decided to switch to analysing our data using
nonparametric tests such as Mann–Whitney instead of stu-
dent t-test and Kruskal-Wallis test instead of ANOVA. This
helped us to compare the groups with fewer assumptions
than might have been required by parametric tests.
IL-1 β
Table 2 shows that there was not a significant difference
in serum concentration of IL-1 β between the two groups
at baseline (p = 0.36, t = 0.93, degrees of freedom (df)
46). A two-way analysis of variance showed that the differ-
ence between patients receiving celecoxib or placebo was
not significant as indicated by the effect on the group, the
between-subjects factor (Greenhouse–Geisser correction: F
0.28, df 1, p = 0.60). The behaviour of two treatments was
similar across the time (groups-by-time interaction, Green-
house–Geisser correction: F 0.42, df 2.17, p = 0.67). The
difference between the two treatments at the endpoint (after
the sixth ECT) was not significant (Mann-Whitney test p
= 0.81). In addition, a one-way repeated measure analysis
of variance did not show a significant effect of both treat-
ments on IL-1β. The p-values of Kruskal-Wallis test for the
celecoxib and the placebo group were 0.57 and 0.95, re-
spectively.
IL-6
Table 2 shows that there was a significant difference in
serum concentration of IL-6 at baseline between groups
(Mann-Whitney test p = 0.004). A two-way analysis of
variance showed that the difference between patients re-
ceiving celecoxib or placebo was not significant as indic-
ated by the effect on the group, the between-subjects factor
(Greenhouse–Geisser correction: F 1.15, df 1, p = 0.22).
The behaviour of two treatments was similar across the
time (groups-by-time interaction, Greenhouse–Geisser cor-
rection: F 1.58, df 2.26, p = 0.21). The difference between
the two treatments at the endpoint (after the sixth ECT) was
not significant (Mann-Whitney test p = 0.39).
Additionally, the changes at the endpoint compared with
baseline were 1.92 and 5.89 for the celecoxib and placebo
groups, respectively, and were not significant (Mann-Whit-
ney test, p = 0.22). In addition, a one-way repeated meas-
ures analysis of variance did not show a significant effect
from both treatments on IL-6. The p-values of Kruskal-
Wallis test for the celecoxib and the placebo group were
0.25 and 0.16, respectively.
TNF-α
Table 2 shows that there was no significant difference in
serum concentration of TNF-α between groups at baseline
(p = 0.09, t = 1.71, df 46). A two-way analysis of variance
showed that the difference between patients receiving cele-
coxib or placebo was not significant as indicated by the
effect on the group, the between-subjects factor (Green-
house–Geisser correction: F 1.67, df 1, p = 0.20). The
behaviour of two treatments was similar across the time
(groups-by-time interaction, Greenhouse–Geisser correc-
tion: F 0.95, df 2.44, p = 0.40). The difference between the
two treatments at the endpoint (after the sixth ECT) was
significant (p = 0.04, t = 2.14, df 46). In addition, a one-
way repeated measures analysis of variance did not show
a significant effect from both treatments on TNF-α. The
p-values of Kruskal-Wallis test for the celecoxib was 0.66
and the p-value of one-way ANOVA for the placebo group
was 0.84.
hsCRP
Table 2 shows that there was no significant difference in
the serum concentration of hsCRP between the groups at
baseline (Mann-Whitney test p = 0.81). A two-way analys-
is of variance showed that the difference between patients
receiving celecoxib or placebo was not significant as indic-
ated by the effect on the group, the between-subjects factor
(Greenhouse–Geisser correction: F 0.16, df1 p = 0.69).
The behaviour of two treatments was similar across the
time (groups-by-time interaction, Greenhouse–Geisser cor-
rection: F 0.64, df 1.59, p = 0.5). The difference between
the two treatments at the endpoint (after the sixth ECT) was
not significant (Mann-Whitney test p = 0.45). In addition,
a one-way repeated measures analysis of variance did not
show a significant effect from both treatments on hsCRP.
The p-values of Kruskal-Wallis test for the celecoxib and
the placebo group were 0.95 and 0.85, respectively.
All patients were closely monitored for adverse effects.
In the celecoxib group one patient developed diarrhea,
however the association of this adverse event with the treat-
ment was not clear. Another patient in this group experien-
ced a rise in blood pressure even though he had a history of
hypertension that was under control prior to ECT.
Discussion
We hypothesised that celecoxib may effectively reduce
some inflammatory factors in patients undergoing ECT.
Thus, the present study was performed to assess the effects
of this medication on these markers in patients suffering
BD who were receiving ECT. The results showed that cele-
coxib could only exert significant effect on TNF-α level at
the end of the study.
A few studies have assessed the effects of adjuvant cele-
coxib on serum cytokines in psychiatric patients. A six-
week trial found a significantly greater reduction in serum
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IL-6 concentrations in patients with major depressive dis-
order (MDD) who received celecoxib in addition to ser-
traline compared with those on placebo and sertraline [33].
On the other hand, another study noted that the addition
of either celecoxib or placebo to the medication regimen
of schizophrenic subjects, who were stabilised on olanza-
pine or risperidone, did not result in changes in cytokines
[34]. Besides, even after one week of the treatment, tem-
porary increases in the levels of TNF-α and IL-2 in patients
receiving olanzapine were observed. The above study con-
cluded that celecoxib does not signiﬁcantly modify levels
of interferon (IFN) γ, IL-1β, IL-2, IL-6, IL-10 or TNF-α in
schizophrenic patients receiving psychotropics. However,
in our study the baseline serum concentrations of Il-6 were
significantly different between the groups. We assessed the
changes in IL-6 concentrations from the baseline levels to
the levels after the sixth ECT session; again the analysis did
not result in any significant difference between groups.
To the best of our knowledge this was the first time that the
effects of celecoxib on cytokines and hsCRP levels in BD
patients undergoing ECT were evaluated. It should be men-
tioned that the clinical effects of adjuvant celecoxib in BD
patients experiencing a depressive or mixed episode was
evaluated in a six week study by Nery et al. [30]. The au-
thors noted a greater improvement in depression in the first
week in patients receiving celecoxib. However, no differ-
ence was reported in the severity of depression or mania
from week two through the end of the trial between the
study groups.
Our study noted a significant difference in the last TNF-
α level measured between the two groups. However, the
differences between the groups were not significant for
hsCRP, IL-6 and IL-1. Hestad et al. suggested that TNF-α
levels may decline in patients receiving repeated ECT [19].
TNF-α level was measured in depressed patients who un-
derwent ECT and was compared with those in depressed
patients not receiving ECT and also in healthy controls.
Gradual and significant decline in TNF-α levels were ob-
served in patients receiving ECT. At the end of the study,
patients who received ECT had TNF-α levels within nor-
mal limits. The authors suggested that ECT could result in
immunomodulatory effects. They proposed that, the anti-
inflammatory effects of ECT may be exerted by electrical
stimulation or secondary to the effects of ECT on neur-
otransmitters or neuroendocrine mediators. Our study did
not find a constant trend in decreasing TNF-α level in the
placebo group. In addition, there is evidence in the literat-
ure for the acute innate immune response activation follow-
ing ECT (e.g. as reported in a study by Fluitman et al. [21])
in patients suffering from medication-resistant MDD and
MDD with psychotic features. The authors noted that ECT
resulted in increased levels of IL-6 and TNF-α. They also
noted that the increases in the levels of cytokines between
different ECT sessions was not significantly different. In
another study, Lehtima et al. [35] reported that IL-1β and
IL-6 were both increased 3 hours after ECT in 9 MDD pa-
tients who underwent one session of ECT; IL-6 was still in-
creased 6hours after ECT, however, both levels decreased
to the baseline values at 24 hours.
We did not find a significant difference in hsCRP levels
between the two groups during the study. Controversies ex-
ist about the CRP-lowering effect of NSAIDs, including
COX-II inhibitors. For example, reduction in CRP levels
was reported after four weeks of treatment with celecoxib
(200 mg daily) in patients undergoing chronic peritoneal
dialysis [36]. In another study in male patients with severe
coronary artery disease who were on aspirin and statins
on a regular basis, hsCRP was significantly reduced two
weeks after addition of celecoxib (200 mg twice daily)
[37]. Additionally, rofecoxib (25 mg daily) taken in com-
bination with aspirin for three months significantly de-
creased CRP levels in patients with acute coronary syn-
drome [36]. On the contrary, a randomised, double-blind
trial reported that the addition of rofecoxib (25 mg daily) or
placebo to the treatment regimen of patients with coronary
artery disease for a period of eight weeks did not produce
a signiﬁcant change in hsCRP and sIL-6r [38]. Similarly,
in another randomised, double-blind trial, four weeks of
treatment with celecoxib (200 mg daily) or placebo could
not modify CRP in overweight or obese volunteers [39].
Moreover, a recent meta-analysis of randomised controlled
trials that assessed the effect of NSAIDs on CRP levels
Table 2: Serum cytokines and hsCRP concentrations in the celecoxib group (n = 25) and placebo group (n = 23) at different assessments during the study. Data are
presented as mean ± standard deviation.
IL-1β (pg/ml) IL-6 (pg/ml) TNF-α (pg/ml) hsCRP (mg/l)
Placebo Celecoxib Placebo Celecoxib Placebo Celecoxib Placebo Celecoxib
Baseline 4.62 ± 5.52 6.03 ± 4.99 5.63 ± 10.39 7.72 ± 23.42 18.69 ± 7.00 14.88 ± 8.30 6.32 ± 13.08 7.65 ± 15.47
First ECT 5.61 ± 7.74 6.72 ± 9.01 26.92 ± 36.69 10.83 ± 27.82 19.16 ± 9.13 17.05 ± 11.76 7.30 ± 14.94 5.60 ± 9.25
Third ECT 10.45 ± 25.64 7.68 ± 14.54 8.58 ± 21.90 2.78 ± 4.85 17.24 ± 7.10 19.36 ± 19.28 5.08 ± 7.17 2.86 ± 2.79
Sixth ECT 9.60 ± 25.59 5.48 ± 6.09 11.53 ± 28.23 9.65 ± 24.25 17.96 ± 7.05 13.70 ± 6.74 5.29 ± 7.35 3.53 ± 6.26
Table 3: Median and interquartile range (IQR) of serum cytokines and hsCRP concentrations in the celecoxib group (n = 25) and placebo group (n = 23) at each
assessment.
IL-1β (pg/ml) IL-6 (pg/ml) TNF-α (pg/ml) hsCRP (mg/l)
Placebo Celecoxib Placebo Celecoxib Placebo Celecoxib Placebo Celecoxib
Baseline 3.8 (0.1‒5.6) 5.4 (3.2‒7.7) 2.2 (1.2‒5.4) 1 (0.8‒1.5) 18.4
(13.3‒20.2)
11.8 (8.2‒20.9) 2.4 (0.1‒4.8) 1.7 (0.4‒5.8)
First ECT 3.4 (2.2‒7) 4.6 (3‒5.8) 3.2 (1.2‒44.4) 1.2 (1‒2.4) 17.1
(12.1‒21.7)
12.5 (9.2‒21.9) 2.3 (0.7‒5.9) 2.3 (0.3‒5.06)
Third ECT 4 (1.8‒7.4) 4.4 (2.2‒6) 1.6 (1.2‒3.2) 1 (0.8‒2.2) 15.2
(11.7‒20.2)
13.5
(9.9‒18.45)
1.9 (0.7‒5.4) 2.4 (0.7‒3.5)
Sixth ECT 3.7 (2‒5.4) 4 (2.2‒6.5) 1.4 (1‒3.4) 1.2 (0.8‒4.4) 16.8
(12.5‒20.9)
10.5
(9.05‒19.4)
1.57(0.3‒6.7) 1.2 (0.7‒3.4)
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in patients suffering from rheumatoid arthritis noted that
some NSAIDs, including celecoxib, had no effects on the
CRP level [40].
One reason why significant changes in cytokines (except
for TNF-α) were not observed after administration of cele-
coxib in our study may be the fact that ECT itself can in-
duce acute production of cytokines. Therefore, in order to
show its anti-inflammatory effects, celecoxib should over-
come not only the high baseline cytokine levels in BD pa-
tients but also the rising levels following ECT.
It should be noted that although the sample size in this
study was calculated to give our study a power of 80%,
wide variation in the serum concentration of different cy-
tokines in the present study makes it difficult to suggest any
sample size for future studies with acceptable thresholds of
power and precision. However, a larger sample size may in
fact result in a more powerful comparison of differences in
the effects of celecoxib on the cytokine levels of the study
patients.
Limitations
Despite the novelty of our study, the limitations should be
emphasised. The use of different mood stabilisers by our
patients can be a potential limitation for our study. Mood
stabilisers have a predominant anti-inﬂammatory effect [6],
which might have interfered with our assessments. Addi-
tionally, increasing the number of assessments after the ini-
tiation of the study could give a more precise result. Anoth-
er possible limitation was the short duration of our study.
A longer study with a larger sample size may show differ-
ent anti-inflammatory effects of celecoxib in BD patients
who are undergoing ECT. Besides, administration of higher
doses of celecoxib may exert a more anti-inflammatory ef-
fect in these patients; however, researchers should be aware
of the possibility of increased ADRs.
Conclusion
This study noted a significant difference only in TNF-α
levels in patients received celecoxib compared with those
received placebo, and no significant changes in other in-
flammatory markers including hsCRP, IL-1β and IL-6 were
observed. The authors suggest a longer duration for invest-
igating the effects of celecoxib on inflammatory markers
with larger number of patients to confirm the findings of
this study.
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Appendix
Many popular and commonly used statistical tests such as
t-tests, analysis of variance (ANOVA), and linear regres-
sion analysis require an important assumption, which is a
normal distribution of the variable(s) of interest. Violation
of the normality assumption makes the interpretation and
inferences unreliable or invalid. Thus, formal theorydriv-
en tests of normality have been developed – in addition
to graphical methods – to check the normal distribution of
variable(s) of interest; Kolmogorov-Smirnov (KS) is one of
the most popular ones available in statistical software pack-
ages [1]. In the KS test, given data are compared with a
normal distribution that takes its mean and variance from
the sample. Then this newly-developed “empirical distribu-
tion function” of the sample is compared to a “cumulative
distribution function” of the reference distribution [2].
In repeated measures ANOVA, sphericity is an important
assumption. It means that the differences between all pos-
sible pairs of levels of the independent variable should have
equal variances. The purpose of the Mauchly’s sphericity
test is to validate repeated measures ANOVA. It determines
if variances of the differences have statistically significant
difference from each other. If the probability of Mauchly’s
test statistic is p <0.05 (i.e., significant), the variances of
the differences are statistically different; so sphericity can-
not be assumed and the F-value is biased upward and the
chance of type I error increases. In order to correct the F-
value, a few correction methods are included in statistical
software packages. Greenhouse-Geisser is one of the most
popular and more conservative ones that is used popularly.
It does not change the F-value; instead, it changes the de-
gree of freedom, such that a valid critical F-value can be
obtained [3].
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